After AstraZeneca walked away from a oncolytic virus vaccine partnership in May, French biotech Transgene was in sore need of a new direction. Enter new CEO Alessandro Riva, a man determined to deliver a proof of concept for the company.

Following its decision to maintain a stock listing for SillaJen earlier this month, the Korea Exchange has done the same for Kolon TissueGene, which had faced delisting but has resumed trading amid decisive moves to improve its business.

The long-standing SillaJen saga in Korea appears close to ending following a decision that the company can maintain its stock market listing. Shares in the oncolytic virus firm surged by their daily limit on the resumption of trading, on hopes it will be able to get back on track.

Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.